Long Noncoding RNA MIR100HG Knockdown Attenuates Hepatocellular Carcinoma Progression by Regulating MicroRNA-146b-5p/Chromobox 6

Abstract

Purpose. Hepatocellular carcinoma (HCC) accounts for approximately ninety percent of primary liver cancer. This study attempted to investigate the effects of the long noncoding RNA MIR100HG (MIR100HG) in HCC and the underlying molecular mechanism. Materials and Methods. qRT-PCR was implemented to analyze the expression of MIR100HG, microRNA-146b-5p (miR-146b-5p), and Chromobox 6 (CBX6). The correlation between MIR100HG and clinicopathological features of HCC patients was assessed. Additionally, the effects of MIR100HG knockdown on HCC cell viability, migration, and invasion were explored. The interactions among MIR100HG, miR-146b-5p, and CBX6 were confirmed. Furthermore, rescue experiments were conducted to investigate whether MIR100HG knockdown modulates HCC cell behaviors through modulating the miR-146b-5p/CBX6 axis. Results. The expression of MIR100HG and CBX6 was enhanced, while miR-146b-5p was inhibited in HCC cells. High MIR100HG expression was positively associated with the TNM tumor stage and Edmondson-Steiner grading in HCC patients. MIR100HG knockdown considerably reduced the HCC cell viability, migration, and invasion. In addition, MIR100HG directly targeted miR-146b-5p, and miR-146b-5p directly targeted CBX6 in HCC cells. Moreover, miR-146b-5p suppression or CBX6 elevation evidently rescued the suppressed viability, migration, and invasion of HCC cells caused by MIR100HG knockdown. Conclusions. Knockdown of MIR100HG inhibited the viability, migration, and invasion of HCC cells by targeting the miR-146b-5p/CBX6 axis, offering a potential therapeutic target for HCC therapy.

A cuproptosis-related LncRNA signature: Integrated analysis associated with biochemical recurrence and immune landscape in prostate cancer

“…LncRNA MIR100HG was dysregulated in many cancers and played distinctively complex and contradictory roles, which involved tumorigenesis, proliferation, and invasion or inhibition of these biological behaviors of tumors (Wu et al, 2022). Previous studies had demonstrated that lncRNA MIR100HG was identified as an oncogene in various cancers, including breast cancer (Chen et al, 2020), hepatocellular carcinoma (HCC) (Li et al, 2021), gastric Frontiers in Genetics frontiersin.org cancer (Li J. et al, 2019;Li et al, 2020), and colorectal cancer (Li W. et al, 2019). However, studies in MIR100HG also proved that it could exert tumor suppressive effects in papillary-thyroid carcinoma (Yang et al, 2021;Park and Lee, 2022) and cervical cancer (Lang et al, 2022;Lin et al, 2022).…”

Development and validation of pyroptosis-related lncRNAs prediction model for bladder cancer

“…MIR100HG plays an important role in human tumors and is an lncRNA that has received a lot of attention in the tumors, and it is expressed differently in tumor tissues dependent on the type of tumor. MIR100HG is involved in tumor proliferation, migration, and invasion in breast cancer [ 34 ], liver cancer [ 35 ], and laryngeal squamous cell carcinoma [ 36 ]. Down-regulation of MIR100HG expression in gastric cancer inhibits proliferation, migration, and invasion of gastric cancer cells [ 37 ].…”

The Long Noncoding RNA MEG3 Retains Epithelial-Mesenchymal Transition by Sponging miR-146b-5p to Regulate SLFN5 Expression in Breast Cancer Cells

“…Subsequently, it is predicted that miR-146b-5p regulates both SLFN5 and MEG3 by RNA hybridization and confirmed that MEG3 can directly bind to miR-146b-5p by RNA pull down assay. However, miR-146b-5p showed the dual functions of promoting or inhibiting tumorigenesis in cancer [41][42][43][44][45]. For instance, Qu L et al reported that miR-146b-5p can promote Ewing's sarcoma malignancy by inhibiting B-cell translocation gene 2 expression [45].…”